Read about rapid innovation in oncology & the pressures healthcare ecosystems & processes are under.

1. Empower oncologists.
Revolutionize biopharma.
Accenture Life Sciences
New Science.
Transformative patient outcomes.

2. The convergence of science and technology make treatment
decisions more complex and oncologists urgently need support
to make the best treatment decision for patients.
In this rapidly changing landscape, biopharma companies can
differentiate themselves from competitors by meeting the individual
needs of oncologists in new, tailored ways that improve patient outcomes.
2
Copyright © 2021 Accenture. All rights reserved.
Science & technology
are converging

3. 3
Copyright © 2021 Accenture. All rights reserved.
The survey was split evenly
between oncologists in academic
medical centers and community
practices. Our results identified
the support and services they
need to focus more on patients.
Accenture
surveyed 120
oncologists
across the US
and Germany

4. How can biopharmaceutical
companies empower oncologists
in this complex environment?
4
Copyright © 2021 Accenture. All rights reserved.

5. 5
Copyright © 2021 Accenture. All rights reserved.

6. Most services require only a general medical background. However,
there are a handful of advanced services that require experienced
oncologists or specialists.
Medical background
is sufficient
An understanding of oncology
would be ideal but is not
mandatory for many services
Experienced
oncologist desired
Peer-to-peer discussions
are desired for some
advanced services
Additional
specialization required
This includes discussions
on genomic sequencing,
biomarkers, genomic or biomarker
results, and molecular pathways
related to specific indications
6
Copyright © 2021 Accenture. All rights reserved.
Who should deliver the support?

7. 43 percent of all oncologists believe that real world data (RWD) and clinical
trial data (CTD) will be equally important sources of clinical decision support
data going forward.
RWD is being seen as a top 5 priority service
of oncologists say they “will need
more discussion” on RWD in the future
of oncologists want pharma
representatives to discuss RWD with them
65%
51%
7
Copyright © 2021 Accenture. All rights reserved.
Overall
Community
practitioners
Academic
medical centers
43%
28%
57%
Oncologists that believe RWD and CTD will
equally inform treatment decisions in the
next 10 years
Focus on two types of data

8. Technology is expected
to become the key force
shaping treatment
decisions going forward
Discussions with
biopharma representatives
are expected to become
less important
Factors that will shape treatment decisions going forward
8
Copyright © 2021 Accenture. All rights reserved.
Technology’s new role
in clinical decisions

9. Human interaction is vital
as face-to-face and virtual
ranked highest
Newer channels—smartphone
apps and social media—
ranked equal or preferred
over meetings and e-mail
Preferred interaction channels for oncologists
9
Copyright © 2021 Accenture. All rights reserved.
Physicians preferred information
access channels

10. The services critical to the future of oncology can be grouped
into these imperatives.
Patient specific discussions
Strengthening the focus on medical
capabilities
Getting the basics right
Recognizing the different needs of
academic medical centers and community
practice oncologists
01
04
Real-world data capabilities
Training field forces and non-customer-facing
employees with deep RWD expertise
02
Precision oncology support
Broadening services for greater access
to peers and experts
03
10
Copyright © 2021 Accenture. All rights reserved.
Four imperatives for biopharma

11. Innovative and excellent
oncologist interaction will
separate leaders from
followers, ultimately
enabling differentiated
outcomes for patients and
health care ecosystems.
Here are three things biopharma companies
should do to set themselves apart:
Act now to be
future ready
Co-create new peer network ecosystems
Build a future-ready customer facing team
Leverage new technology to drive insights
11
Copyright © 2021 Accenture. All rights reserved.

12. 12
Copyright © 2021 Accenture. All rights reserved.
For more information
Access the full report for more
information here.
To learn how Accenture is helping clients
manage and drive exceptional growth in
precision medicine, visit here.
Authors
Dr. Boris Bogdan
Managing Director, Lead—Global
Precision Oncology and PHC, Life Sciences
boris.bogdan@accenture.com
Dr.AndréT.Dahinden
Managing Director, Co-Lead—Global
PrecisionOncology and PHC, Life Sciences
andre.dahinden@accenture.com
Dr.AbhishekKurne
Principal Director, Life Sciences, Accenture
abhishek.kurne@accenture.com
Dr. Sandra Dietschy-Kuenzle
Senior Principal, Life Sciences, Accenture
s.dietschy-kuenzle@accenture.com